膀胱鳞状细胞癌八例

目的　探讨膀胱鳞状细胞癌的发病、诊断、治疗及预后。方法　临床资料回顾性分析。结果　本病占同期膀胱肿瘤 3 4% ,均有膀胱刺激症和血尿 ,3例并有膀胱结石 ,4例伴有前列腺增生。按JEWTT分期 :B期 5例 ,C期 2例 ,D期 1例。本组病例均经病理确诊。结论　膀胱鳞癌治疗效果及预后均较差。     

膀胱鳞状细胞癌诊疗体会

目的：探讨膀胱鳞状细胞癌的病因、诊断与治疗。方法：回顾性分析8例膀胱鳞癌患者的临床资料,复习相关文献。结果：2例行膀胱部分切除术,6例行膀胱全切术,术后均行放疗或免疫疗法,行膀胱部分切除术者至今仍生存1例,为结合免疫治疗患者,1例死亡者由于恶性肿瘤转移。行膀胱全切术者6例,至今生存2例,3例死亡,此3例均由于恶性肿瘤多发转移,1例失访。结论：膀胱鳞癌的预后较差,大多数患者在被诊断时已属晚期,膀胱鳞癌的恶性程度较高,早期诊断和治疗非常重要,行膀胱全切术效果较确实,术后结合免疫疗法可延长生存时间。     

膀胱鳞状细胞癌诊疗体会

目的:探讨膀胱鳞状细胞癌的病因、诊断与治疗。方法:回顾性分析8例膀胱鳞癌患者的临床资料,复习相关文献。结果:2例行膀胱部分切除术,6例行膀胱全切术,术后均行放疗或免疫疗法,行膀胱部分切除术者至今仍生存1例,为结合免疫治疗患者,1例死亡者由于恶性肿瘤转移。行膀胱全切术者6例,至今生存2例,3例死亡,此3例均由于恶性肿瘤多发转移,1例失访。结论:膀胱鳞癌的预后较差,大多数患者在被诊断时已属晚期,膀胱鳞癌的恶性程度较高,早期诊断和治疗非常重要,行膀胱全切术效果较确实,术后结合免疫疗法可延长生存时间。     

膀胱鳞状细胞癌八例

目的 探讨膀胱鳞状细胞癌的发病、诊断、治疗及预后。方法 临床资料回顾性分析。结果本病占同期膀胱肿瘤３．４％，均有膀胱刺激症和血尿，３例并有膀胱结石，４例伴有前列腺增生，按ＪＥＷＴＴ分期：Ｂ期５例。Ｃ期２例，Ｄ期１例。本组病例均经病理确诊。结论 膀胱鳞癌治疗效果及预后均较差。     

膀胱鳞状细胞癌15例报告

 膀胱鳞状细胞癌是较为少见的膀胱上皮肿瘤 ,我院 1978年 2月至 1997年 10月共收治膀胱恶性肿瘤 833例 ,其中经病理证实为膀胱鳞状细胞癌 15例 ,占 1 8%。报告如下。临床资料 :本组 15例 ,男 12例 ,女3例。年龄 34岁～ 76岁 ,平均 5 6 8岁。主要临床表现为肉眼全程血尿、终末血尿及镜下血尿 ;膀胱刺激症状及尿路感染 ;3例有膀胱结石史。 10例行尿脱落细胞检查 ,7例阳性。行静脉尿路造影13例 ,7例显示有单、双侧肾积水或肾功能不全 ,4例有膀胱充盈缺损。Ｂ超检查 9例 ,均提示膀胱内占位性病变。5例行ＣＴ扫描检查者 4例显示肿瘤已浸润至膀胱全层及前列腺组织 ,其中 1例有盆腔淋巴结转移。 15例均行膀胱镜检查 ,9例肿瘤无蒂 ,表面呈地毯样、结节状或桑椹状。粘膜肿胀呈大泡状 ,其表面有坏死组织并可见尿盐沉着。肿瘤发生部位有三角区、底后部、顶部、侧壁及颈部。肿瘤大小 2～ 6ｃｍ。 15例经病理检查均为膀胱鳞状细胞癌 ,其中低分化鳞状细胞癌 5例 ,角化型鳞状细胞癌 4例 ,溃疡型鳞状细胞癌 3例 ,移行细胞癌化生鳞状细胞癌 4例。本组病例按ＴＮＭ临床分期 :Ｔ2 3...     

膀胱鳞状细胞癌12例报告

膀胱鳞状细胞癌 (以下简称鳞癌 )较少见 ,我院 1988年 3月～ 2 0 0 2年 6月收治 12例 ,现报告如下。1　临床资料本组男性 10例 ,女性 2例 ;年龄 45～ 78岁 ,平均 62 .6岁 ;6例有吸烟史。主要症状为血尿 ,其中伴膀胱刺激症状者 8例 ,伴排尿中断者 2例。病程 2～ 9个月。实验室检     

头颈部鳞状细胞癌靶向治疗进展

每年全世界大约有65万例新的头颈癌病例出现,其中绝大多数是头颈部鳞状细胞癌.晚期头颈部鳞状细胞癌的治疗需要综合治疗,尽管放化疗及手术治疗手段在不断发展,但是预后仍不理想且具有一定的毒副反应.靶向治疗是目前治疗研究头颈部鳞癌的热点,其在针对头颈部鳞癌的治疗特别是对局部晚期或复发/转移性头颈部鳞癌治疗中展现出了希望.本文综...     

乳腺原发性鳞状细胞癌一例

乳腺原发性鳞状细胞癌（primary squamous cell carcinoma of the breast,SCC）是乳腺癌中一种少见的类型,为乳腺化生性癌的一种,所占比例不到乳腺癌的1％。在组织学上,乳腺鳞状细胞癌与其他部位的鳞状细胞癌并无区别,以癌珠及细胞问桥形成为特点。本文报道本院收治的1例乳腺原发性鳞状细胞癌病例。     

原发性甲状腺鳞状细胞癌42例诊治分析

目的:探讨原发性甲状腺鳞状细胞癌的临床特征和综合治疗效果.方法:回顾性分析我院1964年-2006年收治甲状腺鳞状细胞癌患者42例,22例行原发灶完整切除+患侧侧颈或区域颈淋巴结清扫,其中病理证实有淋巴结转移者18例;13例行原发灶扩大切除;姑息切除术7例,其中2例同时行气管切开.术后行根治性局部放疗37例,剂量为60-75Gy.结果:患者总的半年生存率为52.3%(22/42),1年生存率为28.6%(12/42),2年生存率为19.0%(8/42),中位生存期为10.1个月.结论:甲状腺鳞状细胞癌是罕见的恶性肿瘤,病情发展迅速,预后差.早期发现并进行扩大根治性手术,并辅以足量放疗,能最大限度提高生存率.     

原发性甲状腺鳞状细胞癌：附8例临床分析

原发性甲状腺鳞状细胞癌罕见,国内外文献仅有少数报道。我院1964年至1989年间收治8例,现报道如下。 临床资料 1964年至1989年我院共收治甲状腺恶性肿瘤801例,其中原发性甲状腺鳞癌8例,约占1％。8例均为男性。年龄45岁～67岁,平均55.4岁。病史最短1个月,     

62例阴茎鳞状细胞癌治疗的临床分析

目的:提高阴茎鳞状细胞癌的治疗水平,寻求鳞状细胞癌合理有效的治疗方法。方法:回顾分析62例病理活检证实阴茎鳞状细胞癌治疗的临床资料。结果:除8例拒绝手术治疗外,其余54例均行手术治疗。45例行阴茎部分切除术,9例行阴茎全切加会阴部尿道造口术治疗,腹股沟淋巴结活检术31例,腹股沟淋巴结病理阳性9例,总活检阳性率为29.0%,行腹股沟淋巴结清扫术。5例行阴茎部分切除者3年内复发,再行阴茎全切除并尿道会阴部造口术及髂腹股沟淋巴清扫术。高分化鳞癌43例,中分化鳞癌7例,低分化鳞癌4例;9例术前淋巴结活检有癌转移,腹股沟淋巴结清扫均有转移,盆腔淋巴结转移4例,淋巴结清扫发现转移2例。按照Jackson分期:I期29例;II期13例;III期8例;V期4例。本组62例患者中44例获定期随访2-7年,随访率70.9%。3年、5年生存率分别为90.9%、75%。非手术治疗5年生存率仅为50%。结论:外科手术治疗是目前治疗阴茎鳞状细胞癌的有效方法,淋巴结清扫根据临床分级具体处理,手术联合术后化、放疗是否可减少复发及提高生存率,还需进一步研究。     

食管基底细胞样鳞癌的诊断与治疗

目的 观察食管基底细胞样鳞癌的临床和病理组织学特征,探讨其诊断、鉴别诊断及治疗方法.方法 对23例食管基底细胞样鳞癌患者的临床和病理资料进行回顾性分析.结果 食管基底细胞样鳞癌发病年龄较大,临床表现和影像学特点与鳞癌相似,以溃疡型多见;治疗首选手术,术后应结合放化疗.本组23例食管基底细胞样鳞癌患者的1、2和3年生存率分别为60.9%、21.7%和0.结论 食管基底细胞样鳞癌具有恶性程度高、进展快、转移早和预后差等特点,临床上应采用根治性手术并结合术后放化疗的治疗方案.     

Diagnosis and therapy of oral squamous cell carcinoma

Oral squamous cell carcinoma ranks among the top ten most common cancers worldwide. Despite the success in diagnosis and therapy during the past 30 years, oral squamous cell carcinoma still belongs to the tumor types with a very unfavorable prognosis. In an effort to identify genomic alterations with prognostic relevance, we applied the comparative genomic hybridization technique on oral squamous cell carcinoma. The tumors exhibited from five up to 47 DNA copy number alterations, indicating a considerable degree of genomic imbalance. Out of 35 tumors, 19 showed a gain of chromosome band 7p12. Genomic imbalances were investigated by hierarchical cluster analysis and clustered image mapping to investigate whether genomic profiles correlate with clinical data. Results of the present investigation show that profiling of genomic imbalances in general, and especially of the epidermal growth factor receptor (EGFR) on 7p12, may be suitable as prognostic factors. In order to identify small-molecule inhibitors for EGFR, we established a database of 531 natural compounds derived from medicinal plants used in traditional Chinese medicine. Candidate compounds were identified by correlation analysis using the Kendall tau-test of IC50 values of tumor cell lines and microarray-based EGFR mRNA expression. Further validation was performed by molecular docking studies using the AutoDock program with the crystal structure of EGFR tyrosine kinase domain as docking template. We estimate these results will be a further step toward the ultimate goal of individualized, patient-adapted tumor treatment based on tumor molecular profiling.     

Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder

Recent incidence data from the United States indicate that transitional cell carcinoma accounts for the vast majority (95%) of bladder tumors in this country, with squamous cell carcinoma (less than 3%) and adenocarcinoma (less than 2%) comprising nearly all the remaining cases. Rates of squamous cell carcinoma and adenocarcinoma were higher in blacks compared to whites, while the reverse was true for transitional cell carcinoma. All three tumors predominated in males, especially transitional cell carcinoma. A population-based case-control study of bladder cancer conducted in 10 geographical areas of the United States identified 43 patients with squamous cell carcinoma and 32 with adenocarcinoma to permit an examination of risk factors. Cigarette smoking was significantly associated with risk of squamous cell carcinoma, with the relative risk rising to 6.1 among smokers of 40 or more cigarettes/day. Significantly elevated risks of squamous cell carcinoma were also associated with a history of 3 or more urinary tract infections (relative risk = 5.7) and with employment as welders and cooks. Risk factors were generally less conspicuous for adenocarcinoma, except for a significant trend with the amount of coffee drinking; however, this finding is based on small numbers and should be interpreted cautiously.     

Diagnosis and treatment of renal cell carcinoma

Renal cell carcinoma is one of the most difficult malignant tumors for early diagnosis. It is rare that the classic symptoms such as hematuria, a renal mass and flank pain appear simultaneously. Only in about 7% of renal cell carcinoma patients these symptoms occurred simultaneously. Hematuria is an important symptom, and in our series 46% of the patients with renal cell carcinomas were conscious of macrohematuria as an initial symptom. As an initial symptom, a mass was palpable in 8% and flank pain was felt in 13% of the patients with renal cell carcinomas. Nonurologic symptoms were observed as initial symptoms in 33% cases, suggesting physician's particular attention on these symptoms. Initial diagnosis of renal cell carcinomas begins with urinary tract x-ray examination, which is followed by ultrasonography, CT scan, and if necessary, angiography. These procedures make definite diagnosis possible and define clinical staging. The most basic and reliable treatment method established for renal cell carcinomas is surgery--radical nephrectomy. Much cannot be expected from chemotherapy or radiotherapy as an adjuvant modality. To what extent lymphoadenectomy should be performed at the time of radical surgery is a question still to be definitely answered, but the lymph node of the renal pedicle should be removed completely. While any chemotherapeutic drug or method has not yet been established, an increasing number of useful agents have been studied. Radiotherapy is now used exclusively as adjuvant therapy for metastatic tumors. In order to improve clinical results, it is necessary to establish an appropriate approach according to clinical stage. In particular, establishment of approach to progressive carcinomas is imperative.     

皮肤鳞状细胞癌的外科治疗

目的 探讨皮肤鳞状细胞癌的外科治疗方法及效果。方法 收集1981年12月至2011年12月鳞状细胞癌105例,其中手术治疗101例。切除病灶后,根据创面不同部位、大小、深度,选择任意皮瓣、肌皮瓣或皮片修复创面;创面位于面部及关节部位采用分区植皮方法。结果病灶切除后,移植皮片48例,任意皮瓣或肌皮瓣修复53例;随诊6个月以上85例,随诊5年以上52例,16例发生局部复发或远处转移,其中8例死亡,其余患者术区外形良好,局部无复发。结论 皮肤鳞状细胞癌早期发现行完整手术切除仍然是最佳的治疗手段,对手术缺损可以采用整形美容方法修复,实现患者的生存时间和生活质量的提高。     

Neoadjuvant treatment for esophageal squamous cell carcinoma

Squamous cell carcinoma and adenocarcinoma are types of esophageal cancer, one of the most aggressive malignant diseases. Since both histological types present entirely different diseases with different epidemiology, pathogenesis and tumor biology, separate therapeutic strategies should be developed against each type. While surgical resection remains the dominant therapeutic intervention for patients with operable esophageal squamous cell carcinoma (ESCC), alternative strategies are actively sought to reduce the frequency of post-operative local or distant disease recurrence. Such strategies are particularly sought in the preoperative setting. Currently, the optimal management of resectable ESCC differs widely between Western and Asian countries (such as Japan). While Western countries focus on neoadjuvant or definitive chemoradiotherapy, neoadjuvant chemotherapy followed by surgery is the standard treatment in Japan. Importantly, each country and region has established its own therapeutic strategy from the results of local randomized control trials. This review discusses the current knowledge, available data and information regarding neoadjuvant treatment for operable ESCC.